Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
An article to be published in the July/August issue of CA: A Cancer Journal for Clinicians, but not yet available on line, as well as the accompanying editorial, is causing a flurry of new, and somewhat misleading, media information about the association between individual testing for risk of prostate cancer and the potential of mass [...]
Filed under: Diagnosis, Risk | Tagged: screening | 1 Comment »
A recent study from researchers at the University of California, San Francisco and the Dana-Farber Cancer Center is now suggesting that elevated selenium levels in the blood may worsen prostate cancer outcomes in some men who already have the disease.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: risk, selenium, SOD2, superoxide dismutase | 5 Comments »
The “Reach Out to Enhance Wellness” (RENEW) trial was initiated as a randomized multi-center, multi-national trial to actually prove something which many would consider to be “obvious”: the idea that lifestyle modification will help cancer survivors to avoid the risks that they are at for second malignancies, other comorbidities, and accelerated functional decline.
Filed under: Living with Prostate Cancer, Management | Tagged: lifestyle, quality of life, survival | Leave a Comment »
Today’s news reports deal with such items as: Genomic testing for prostate cancer and the value of specific SNPs What do pre-treatment MRI/MRSI tests and molecular profiling add to prognostic significance? Quality of life following salvage brachytherapy
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: brachytherapy, Diagnosis, genome, MRI, MRSI, prognosis, quality of life, salvage, SNPs | 2 Comments »
Two recent publications have dealt with issues related to the appropriate application of the free/total PSA ratio test in patients at potential risk for prostate cancer.
Filed under: Diagnosis, Risk | Tagged: free/total, PSA, ratio | 2 Comments »
Risk for erectile dysfunction (ED) after prostate cancer treatment is commonly assumed to be a reason why many men avoid being tested for their risk for prostate cancer. Whether that is really true or not is actually not well understood.
Filed under: Diagnosis, Risk | Tagged: ED, erectile dysfunction, screening | Leave a Comment »
A new review makes some strong recommendations regarding the impact of serum levels of 25-hydroxyvitamin D — also known as 25(OH)D — and its metabolites and the effects on risk for several forms of cancer (including aggressive forms of prostate cancer).
Filed under: Prevention | Tagged: Prevention, vitamin D | 4 Comments »
A technique known as sentinel lymph node dissection (SLND) has replaced extended lymphadenectomy for nodal staging in several types of solid tumor cancers.
Filed under: Diagnosis, Management, Risk | Tagged: dissection, lymph node, sentinel | Leave a Comment »
Today’s prostate cancer news report summary includes items dealing with: The epigenetics of prostate cancer and their potential importance Selenium + vitamin E + lycopene (in mice) Gleason 7: 4 + 3 versus 3 + 4 — it’s important Proton beam radiotherapy — a topical review EBRT + low dose, permanent seed brachytherapy
Filed under: Diagnosis, Management, Prevention, Risk, Treatment | Tagged: brachytherapy, EBRT, epigenetics, Gleason 3 + 4 4 + 3, lycopene, PBRT, proton beam, selenium, vitamin E | 2 Comments »
A report in this week’s issue of the New England Journal of Medicine (which is never shy about promoting itself) provides more early, and interesting, evidence of the future potential of so-called PARP inhibitors in cancer therapy.
Filed under: Drugs in development, Management, Treatment, Uncategorized | Tagged: MSI-201, olaparib, PAP inhibitor | Leave a Comment »
The relative merits of proton beam radiotherapy (PBRT) and the more commonly available intensity-modulated radiotherapy (IMRT) as forms of external beam radiation for prostate cancer are much debated … with minimal supportive evidence on either side of the debate because no comparative trial has ever been carried out.
Filed under: Management, Treatment | Tagged: cancer, IMRT, intensity-modulated, PBRT, proton beam, radiation, second, therapy | 3 Comments »
Today’s news reports include discussion of items on: Prostate cancer risk awareness Improving cryotherapy technique with 3D ultrasound Interposition (“sural”) nerve grafting Post-brachytherapy “PSA bounce” The potential of targeted, peptide-linked, α-emitting radioisotopes
Filed under: Diagnosis, Drugs in development, Management, Prevention, Risk, Treatment | Tagged: African American, awareness, brachytherapy, cryotherapy, Hispanic, interposition, nerve grafting, PSA bounce, radiopeptides, risk, sural, targeted, therapy | 3 Comments »
OncoGenex Pharmaceuticals has just announced today that the company is “ready to proceed with two Phase 3 trial designs” for its investigational drug OGX-011, “one in first-line and one in second-line treatment of advanced prostate cancer.”
Filed under: Drugs in development, Management, Treatment | 2 Comments »
We have long known that prostate cancer specimens (and specimens for other urologic malignancies) can be very difficult for pathologists to evaluate with accuracy, and that second pathological opinions can be helpful in ensuring an appropriate diagnosis prior to treatment and/or an appropriate prognosis after radical surgery.
Filed under: Diagnosis, Management, Treatment | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site